A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Carfilzomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms A.R.R.O.W.; ARROW
- Sponsors Amgen; Ono Pharmaceutical; Onyx Pharmaceuticals
- 03 Feb 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2019.
- 03 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2019.
- 02 Feb 2017 According to an Amgen media release, results are expected in 2019.